McAlees Eleanor, Vollebregt Paul F, Stevens Natasha, Dudding Tom C, Emmanuel Anton V, Furlong Paul L, Hamdy Shaheen, Hooper Richard L, Jones James F X, Norton Christine, O'Connell P Ronan, Scott S Mark, Knowles Charles H
National Bowel Research Centre, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
University Hospital Southampton NHS Foundation Trust, Southampton, UK.
Trials. 2018 Jun 26;19(1):336. doi: 10.1186/s13063-018-2689-1.
Faecal incontinence (FI) is a substantial health problem with a prevalence of approximately 8% in community-dwelling populations. Sacral neuromodulation (SNM) is considered the first-line surgical treatment option in adults with FI in whom conservative therapies have failed. The clinical efficacy of SNM has never been rigorously determined in a trial setting and the underlying mechanism of action remains unclear.
METHODS/DESIGN: The design encompasses a multicentre, randomised, double-blind crossover trial and cohort follow-up study. Ninety participants will be randomised to one of two groups (SNM/SHAM or SHAM/SNM) in an allocation ratio of 1:1. The main inclusion criteria will be adults aged 18-75 years meeting Rome III and ICI definitions of FI, who have failed non-surgical treatments to the UK standard, who have a minimum of eight FI episodes in a 4-week screening period, and who are clinically suitable for SNM. The primary objective is to estimate the clinical efficacy of sub-sensory SNM vs. SHAM at 32 weeks based on the primary outcome of frequency of FI episodes using a 4-week paper diary, using mixed Poisson regression analysis on the intention-to-treat principle. The study is powered (0.9) to detect a 30% reduction in frequency of FI episodes between sub-sensory SNM and SHAM stimulation over a 32-week crossover period. Secondary objectives include: measurement of established and new clinical outcomes after 1 year of therapy using new (2017 published) optimised therapy (with standardised SNM-lead placement); validation of new electronic outcome measures (events) and a device to record them, and identification of potential biological effects of SNM on underlying anorectal afferent neuronal pathophysiology (hypothesis: SNM leads to increased frequency of perceived transient anal sphincter relaxations; improved conscious sensation of defaecatory urge and cortical/subcortical changes in afferent responses to anorectal electrical stimulation (main techniques: high-resolution anorectal manometry and magnetoencephalography).
This trial will determine clinical effect size for sub-sensory chronic electrical stimulation of the sacral innervation. It will provide experimental evidence of modifiable afferent neurophysiology that may aid future patient selection as well as a basic understanding of the pathophysiology of FI.
International Standard Randomised Controlled Trial Number: ISRCTN98760715 . Registered on 15 September 2017.
大便失禁(FI)是一个严重的健康问题,在社区居住人群中的患病率约为8%。骶神经调节(SNM)被认为是保守治疗失败的成年FI患者的一线手术治疗选择。SNM的临床疗效从未在试验环境中得到严格确定,其潜在作用机制仍不清楚。
方法/设计:该设计包括一项多中心、随机、双盲交叉试验和队列随访研究。90名参与者将以1:1的分配比例随机分为两组(SNM/假手术组或假手术/SNM组)。主要纳入标准为年龄在18-75岁之间、符合罗马III和ICI的FI定义、非手术治疗未达到英国标准、在4周筛查期内至少有8次FI发作且临床适合SNM的成年人。主要目标是基于使用4周纸质日记记录的FI发作频率这一主要结局,在32周时采用意向性分析原则,通过混合泊松回归分析估计亚感觉SNM与假手术相比的临床疗效。该研究的检验效能为0.9,以检测在32周交叉期内亚感觉SNM与假手术刺激相比FI发作频率降低30%的情况。次要目标包括:在使用新的(2017年发表的)优化治疗(采用标准化SNM电极放置)治疗1年后测量既定和新的临床结局;验证新的电子结局指标(事件)及其记录设备,并确定SNM对潜在的肛门直肠传入神经元病理生理学的潜在生物学效应(假设:SNM导致感知到的短暂肛门括约肌松弛频率增加;改善排便冲动的意识感觉以及对肛门直肠电刺激的传入反应中的皮质/皮质下变化(主要技术:高分辨率肛门直肠测压和脑磁图))。
该试验将确定骶神经支配亚感觉慢性电刺激的临床效应大小。它将提供可改变的传入神经生理学的实验证据,这可能有助于未来的患者选择,并增进对FI病理生理学的基本理解。
国际标准随机对照试验编号:ISRCTN98760715。于2017年9月15日注册。